One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

Telix Pharmaceuticals Limited today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

A 61-year-old patient, initially presenting with urinary complaints, has undergone Stereotactic Body Radiation Therapy (SBRT) for prostate cancer at KMC Hospital Attavar Oncology Centre (KMCHAOC) in ...

See α-Synuclein. Candidate tracer SY08 detects α-synuclein deposits in the brainstem (right) and parietal cortex (left) of ...

Cardinal is using its own cyclotron installations to produce Gozellix for distribution across a range of US locations.